Biogen Inc
(MIL:1BIIB)
€
141.3
0 (0%)
Market Cap: 20.87 Bil
Enterprise Value: 25.62 Bil
PE Ratio: 13.49
PB Ratio: 1.33
GF Score: 53/100 Biogen Inc Evaluation Of Aducanumab Efficacy And Safety In Early Alzheimer's Disease Discussion at AD/PD Conference Call Transcript
Mar 13, 2021 / 11:45AM GMT
Randall J. Bateman
We're going to be discussing the amyloid beta targeting therapies in Alzheimer's disease session 2. I'm Randy Bateman. I'm a Professor of Neurology at Washington University and the Director of The Dominantly Inherited Alzheimer's Network and Trials Unit. Chad?
Chad Swanson
Hi, everybody. I'm Chad Swanson in the Neurology Business Group at Eisai and Clinical Development, and I am the international project team leader for aducanumab or BAN24 (sic) [BAN2401].
Randall J. Bateman
Great. And Mark?
Mark A. Mintun
I'm Mark Mintun, and I head the Alzheimer's disease development area for Eli Lilly and Company.
Randall J. Bateman
Great. And Samantha?
Samantha Budd Haeberlein
Biogen Inc. - VP of Clinical Development
Hi there. Good morning, good afternoon. I'm Samantha Budd. I work at Biogen, and I head up the Neurodegeneration Development group. Thank you.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot